We chose CD19 or CD38 as second tumor target, because both antigens are co-expressed with CD20 on a variety of B cell lymphomas or leukemias making these tumor antigen combinations ideal for the dual-dual-targeting approach. This evidence concerns the gene CD19 and leukemia.